Biohacker Takes 120mg Melatonin Daily for a Week and Reports Surprising Results

Melatonin megadosing represents a fascinating frontier in longevity research, moving far beyond its traditional role as a sleep supplement. Biohacker Siim Land's week-long experiment with 120mg nightly doses - 100 times higher than typical sleep dosages - offers insights into melatonin's potential as an anti-aging compound when used at pharmacological levels.

Land's personal experience revealed both benefits and drawbacks. He consistently woke at 4 AM feeling completely refreshed, as if he had slept a full eight hours. However, daytime side effects included mild headaches and increased irritability, suggesting that megadosing affects more than just sleep architecture.

The scientific foundation for high-dose melatonin comes from a comprehensive 2021 meta-analysis examining 79 clinical trials using doses ranging from 10mg to 3,000mg. This research demonstrated melatonin's safety profile at extreme doses while revealing diverse therapeutic applications. In dementia patients, high-dose melatonin improved sleep regulation while providing anti-amyloid and neuroprotective effects. Cancer patients receiving melatonin alongside chemotherapy experienced better treatment tolerance and possible anti-tumor benefits. Cardiovascular patients saw reduced blood pressure, improved cholesterol profiles, and decreased inflammation markers.

The implications for longevity are significant, as melatonin at megadoses appears to function primarily as a potent antioxidant and anti-inflammatory agent rather than a sleep aid. This dual mechanism could address multiple aging pathways simultaneously. However, Land's experience highlights the need for careful consideration of dosing protocols and potential side effects. While the research shows promise, individual responses vary considerably, and the long-term effects of sustained megadosing remain unclear, warranting further clinical investigation.